Latest Novartis Stories
The Acute Heart Failure Market Will Also Experience Substantial Growth Following the Launch of Two Novel Vasodilator Therapies, According to Findings from Decision Resources Group BURLINGTON,
Young Law Group announces court decision in a qui tam lawsuit alleging payments to doctors for sham speaker programs against Novartis on the day of the first public release by the Government of
WOODCLIFF LAKE, N.J., Sept. 30, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc.
BASEL, Switzerland, Sept. 29, 2014 /PRNewswire/ -- Syngenta today announced that John Atkin, Chief Operating Officer, will retire from the company at the end of 2014.
- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER,
A recent breakthrough in clinical results with an experimental drug to treat heart failure has shown very promising results.
New research report “Global Cancer Vaccines Market & Pipeline Analysis” worked out by Kuick Research is now available at MarketPublishers.com. London,